Photonic blood typing
Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.
1. A photonic system for testing a sample to determine a blood type, comprising:
(1) a first photonic device for determining the blood type, comprising:
a first sample waveguide having a first sample surface; and
a first binding coating covering and in optical communication with at least a portion of the first sample surface, the first binding coating being configured to directly bind to a blood cell target moiety in the sample indicative of the blood type, wherein the blood cell target moiety is attached to a blood cell body selected from the group consisting of a blood cell, a blood cell membrane, a blood cell fragment, a microvesicle, a microparticle, and a blood cell-associated antigen, and wherein the first photonic device is configured such that light passed through the first sample waveguide has an evanescent field that extends a distance beyond the first sample waveguide sufficient to detect the bound blood cell target moiety; and
(2) a second photonic device for determining blood type, comprising:
a second sample waveguide having a second sample surface; and
a second binding coating covering and being in optical communication with at least a portion of the second sample surface, the second binding coating comprising specifically defined antigens configured to bind to an antibody in the sample indicative of immunity to blood antigens, wherein the second photonic device is configured such that light passed through the second sample waveguide has an evanescent field that extends a distance beyond the second sample waveguide sufficient to detect the antibody indicative of immunity to blood antigens, wherein the first photonic device and the second photonic device are configured to simultaneously test the sample.
2. The photonic system of claim 1 , wherein the first photonic device and the second photonic device are configured to simultaneously determine the blood type.
3. The photonic system of claim 1 , further comprising a computer configured to determine the blood type using output from both the first photonic device and the second photonic device.
4. The photonic system of claim 1 , further comprising a reference waveguide in optical communication with the sample that does not have any binding coating.
5. The photonic system of claim 1 , further comprising a third photonic device configured to bind a target moiety in the sample indicative of a pathogen.
6. The photonic system of claim 5 , wherein the target moiety indicative of a pathogen is selected from the group consisting of a pathogen, a pathogen-associated antibody, a pathogen-associated nucleic acid, and a pathogen-associated antigen.
7. The photonic system of claim 1 , wherein the sample is whole blood.
8. The photonic system of claim 1 , wherein the first sample waveguide and the second sample waveguide are each a portion of a photonic device selected from the group consisting of a ring resonator, a Bragg reflector, and a Mach-Zehnder interferometer.
9. The photonic system of claim 8 , wherein the first sample waveguide and the second sample waveguide are each a portion of the same type of photonic device.
10. The photonic system of claim 1 , wherein the first binding coating is antifouling, the second binding coating is antifouling, or the first binding coating and the second binding coating are antifouling.
11. The photonic system of claim 1 , wherein the first binding coating is zwitterionic, the second binding coating is zwitterionic, or the first binding coating and the second binding coating are zwitterionic.
12. The photonic system of claim 1 , wherein the first binding coating comprises a plurality of layers, including an antifouling layer and a capture layer.
13. The photonic system of claim 12 , wherein the capture layer comprises at least one binding moiety configured to directly bind to the blood cell target moiety indicative of blood type.
14. The photonic system of claim 12 , wherein the antifouling layer is bound to the capture layer.
15. The photonic system of claim 1 , wherein the first binding coating is covalently attached to the first sample waveguide.
16. The photonic system of claim 1 , wherein the first binding coating is not bound to the first sample waveguide.
17. The photonic system of claim 1 , wherein the second binding coating comprises a plurality of layers, including an antifouling layer and a capture layer.
18. The photonic system of claim 17 , wherein the capture layer comprises the specifically defined antigens configured to bind to an antibody indicative of immunity to blood antigens.
19. The photonic system of claim 17 , wherein the antifouling layer is bound to the capture layer.
20. The photonic system of claim 1 , wherein the second binding coating is covalently attached to the second sample waveguide.
21. The photonic system of claim 1 , wherein the second binding coating is not bound to the second sample waveguide.
22. The photonic system of claim 6 , wherein the third photonic device comprises a third binding coating, wherein the third binding coating comprises a plurality of layers, including an antifouling layer and a capture layer, wherein the capture layer comprises specifically defined antigens configured to bind to the target moiety in the sample indicative of a pathogen.